Earnings summaries and quarterly performance for ENANTA PHARMACEUTICALS.
Executive leadership at ENANTA PHARMACEUTICALS.
Jay Luly
Detailed
President and Chief Executive Officer
CEO
BL
Brendan Luu
Detailed
Chief Business Officer
MK
Matthew Kowalsky
Detailed
Chief Legal Officer and Corporate Secretary
PM
Paul Mellett
Detailed
Chief Financial and Administrative Officer
SR
Scott Rottinghaus
Detailed
Chief Medical Officer
TK
Tara Kieffer
Detailed
Chief Product Strategy Officer
YS
Yat Sun Or
Detailed
Chief Scientific Officer
Board of directors at ENANTA PHARMACEUTICALS.
Research analysts who have asked questions during ENANTA PHARMACEUTICALS earnings calls.
Eric Joseph
JPMorgan Chase & Co.
4 questions for ENTA
Also covers: BEAM, BLUE, KYMR +9 more
Jay Olson
Oppenheimer & Co. Inc.
4 questions for ENTA
Also covers: ACAD, AMGN, BIIB +22 more
RB
Roy Buchanan
Citizens JMP
2 questions for ENTA
Also covers: ABUS, CDTX, CVAC +5 more
AA
Antonio Arce
H.C. Wainwright & Co.
1 question for ENTA
Also covers: AKBA, CLSD, CODX
M(
Mick (on behalf of Roanna Ruiz)
Leerink Partners
1 question for ENTA
RR
Roanna Ruiz
Leerink
1 question for ENTA
Also covers: CRMD, LXRX, UTHR
TY
Thomas Yip
H.C. Wainwright & Co.
1 question for ENTA
Also covers: ABUS, ARDX, GALT +6 more
WY
Wing Yip
Unspecified
1 question for ENTA
Also covers: ABUS, ACXP, ARCT +2 more
Recent press releases and 8-K filings for ENTA.
Enanta Provides Updates on RSV and Immunology Programs at JPMorgan Healthcare Conference
ENTA
New Projects/Investments
Product Launch
- Enanta is preparing for a Phase 3 study of its lead RSV asset, Ziresovir, in high-risk adults, following successful Phase 2 results that showed a reduction in hospitalization rates from approximately 5% to 1% in the placebo group. Alignment with the FDA on the Phase 3 design is expected in Q2, with readiness for the Q3/Q4 virus season.
- The company is advancing its immunology pipeline, with the IND filing for KIT inhibitor EDP-978 on track for Q1, and Phase 1 data expected in Q4 2026.
- Enanta also plans to file the IND for STAT6 inhibitor EDP-3903 in the second half of 2026, aiming for an oral Dupixent-like profile.
- A new immunology program targeting MRGPRX2 (X2) was announced, with a development candidate expected in the second half of 2026.
Jan 14, 2026, 11:00 PM
Enanta Pharmaceuticals Provides Update on RSV and Immunology Pipeline
ENTA
New Projects/Investments
Guidance Update
- Enanta's lead Respiratory Syncytial Virus (RSV) asset, zelicapavir, demonstrated positive results in two Phase 2 studies, including a reduction in hospitalization rate from 5% to approximately 1% in high-risk adults. The company is preparing for a Phase 3 study and expects alignment with the FDA on its design and registration path in Q2 2026.
- Enanta is actively exploring business development opportunities for zelicapavir, aiming to secure a commercialization partner for what they believe could be the first-ever treatment for RSV.
- The company is advancing its immunology pipeline with several programs: EDP-978 (KIT inhibitor) is on track for an IND filing in Q1 2026 and Phase 1 data in Q4 2026; 3903 (STAT6 inhibitor) is slated for an IND filing in the second half of 2026; and a development candidate for the new MRGPRX2 (X2) program is expected in the second half of 2026.
- Enanta also has EDP-323, another RSV molecule with a different mechanism, which showed 85%-87% viral load reduction in a human challenge study.
Jan 14, 2026, 11:00 PM
Enanta Pharmaceuticals Provides R&D Program Updates and 2026 Outlook
ENTA
New Projects/Investments
Legal Proceedings
Guidance Update
- Enanta Pharmaceuticals is continuing Phase 3 enabling activities for zelicapavir, an RSV N-protein inhibitor, including discussions with the FDA, following positive Phase 2b results. The company is also exploring potential business development opportunities for its RSV assets.
- The company is expanding its immunology pipeline with a new discovery program focused on MRGPRX2 inhibition for chronic spontaneous urticaria (CSU), aiming to select a development candidate in the second half of 2026.
- Enanta is advancing its immunology clinical candidates: EDP-978 (KIT inhibitor) is on track for an IND filing in Q1 2026 and Phase 1 data in Q4 2026, and EPS-3903 (STAT6 inhibitor) is slated for an IND filing in the second half of 2026.
- Enanta maintains a strong financial position with a cash runway expected to fund operations into fiscal 2029, supported by continuing retained royalties.
- A patent infringement action against Pfizer Inc. concerning Paxlovid™ is ongoing in the Unified Patent Court (UPC) of the European Union, with an update expected in the second half of 2026.
Jan 8, 2026, 12:00 PM
Enanta Pharmaceuticals Discusses RSV Program and Immunology Pipeline Expansion
ENTA
New Projects/Investments
Guidance Update
Product Launch
- Enanta Pharmaceuticals reported compelling Phase II-B data for its lead RSV treatment, zelicapavir, in high-risk adults and plans to discuss Phase III trial design with the FDA.
- The company is expanding its pipeline into immunology and inflammation, with two key programs advancing towards clinical trials.
- An Investigational New Drug (IND) application for the KIT inhibitor, EDP-978, for mast cell-driven diseases is on track for Q1 2026.
- An IND for the STAT6 inhibitor, aiming for an oral Dupixent-like profile, is expected in the second half of 2026.
- Enanta plans to announce a third immunology target in the coming weeks.
Dec 3, 2025, 1:20 PM
Enanta Pharmaceuticals Discusses Zelecapavir Phase IIB Data and Immunology Pipeline Progress
ENTA
New Projects/Investments
Product Launch
Guidance Update
- Enanta Pharmaceuticals reported compelling Phase IIB data for its RSV treatment, Zelecapavir, in high-risk adults, noting there is currently no approved treatment for RSV. A Phase III trial is expected to involve 500-700 patients and focus on symptoms and hospitalization.
- The company is advancing its immunology pipeline, with EDP-978, a KIT inhibitor for mast cell-driven diseases, on track for an IND filing in Q1 2026.
- Enanta's STAT6 program, aiming for an oral Dupixent-like profile, has a development candidate with an IND filing expected in the second half of 2026. Preclinical data showed activity in animal models of atopic dermatitis and asthma.
- A third immunology target is planned to be announced in the coming weeks.
Dec 3, 2025, 1:20 PM
Enanta Pharmaceuticals Discusses RSV Program and Immunology Pipeline Expansion
ENTA
New Projects/Investments
Product Launch
Guidance Update
- Enanta Pharmaceuticals reported compelling Phase IIB data for Zelecapavir, its lead molecule for RSV infection, in high-risk adults, noting a week reduction in symptoms and hospitalization in the HR3 subpopulation.
- The company is expanding its pipeline into immunology, with an Investigational New Drug (IND) application for its KIT inhibitor (EDP-978) on track for Q1 2026, and an IND for its STAT6 program expected in the second half of 2026.
- EDP-978 is an oral small molecule KIT inhibitor optimized for nanomolar potency and selectivity, aiming to replicate the efficacy of antibodies in mast cell-driven diseases with potential for daily dosing.
- The STAT6 program's development candidate has demonstrated good activity in animal models of atopic dermatitis and asthma, focusing on selective small molecule inhibitors to provide an oral alternative to existing treatments like Dupixent.
Dec 3, 2025, 1:20 PM
Enanta Pharmaceuticals Provides Updates on RSV and Immunology Programs
ENTA
New Projects/Investments
Guidance Update
- Enanta Pharmaceuticals reported positive data for its RSV therapeutic, Zelicapavir, in a high-risk adult study, demonstrating a shortened time to complete resolution by about a week and a reduced hospitalization rate from approximately 5% to 1%. This data supports advancement into a Phase 3 study.
- The company announced EPS3903 as a development candidate for its STAT6 inhibitor program, with pre-clinical activity comparable to Dupixent, and aims for an Investigational New Drug (IND) filing in the second half of 2026.
- Enanta's KIT program, featuring clinical candidate EDP978, is on track for an IND filing in Q1 2026.
- A third immunology program is expected to be announced in the coming weeks.
Nov 18, 2025, 1:00 PM
Enanta Pharmaceuticals Provides Updates on RSV, STAT6, and KIT Programs
ENTA
New Projects/Investments
Guidance Update
- Enanta Pharmaceuticals reported positive data from its high-risk adult study for Zelicapavir, an RSV therapeutic, which supports its advancement into a Phase 3 study.
- The company announced EPS-3903 as a development candidate for its oral STAT6 inhibitor program, demonstrating pre-clinical activity comparable to Dupixent, with an Investigational New Drug (IND) filing targeted for the second half of 2026.
- An IND filing for EDP-978, a mast cell-targeting KIT inhibitor, is on track for Q1 2026.
- Enanta plans to announce a third immunology program in the coming weeks and is exploring strategic partnership opportunities for its RSV program.
Nov 18, 2025, 1:00 PM
Enanta Pharmaceuticals Provides Updates on RSV and Immunology Programs
ENTA
New Projects/Investments
Product Launch
Guidance Update
- Enanta Pharmaceuticals announced positive data from its high-risk adult study for the RSV therapeutic Zelicapavir, which demonstrated a one-week improvement in time to complete symptom resolution and a reduction in hospitalization rates from approximately 5% to 1% in the treated population, supporting a move to Phase 3.
- In immunology, the company designated EPS3903 as a development candidate for its STAT6 program, showing pre-clinical activity comparable to Dupixent in asthma and atopic dermatitis models, with an IND filing targeted for the second half of 2026.
- Enanta is also on track to file an Investigational New Drug (IND) application in Q1 2026 for EDP978, a clinical candidate targeting KIT.
- The company plans to announce a third immunology program soon and is exploring strategic partnership opportunities for its RSV program.
Nov 18, 2025, 1:00 PM
Enanta Pharmaceuticals Reports Fiscal Q4 and Full-Year 2025 Results, Announces Pipeline Progress, and Strengthens Financial Position
ENTA
Earnings
New Projects/Investments
Guidance Update
- Enanta Pharmaceuticals, Inc. reported a net loss of $18.7 million, or $0.87 per diluted common share, on $15.1 million in total revenue for the fiscal fourth quarter ended September 30, 2025.
- For the full fiscal year ended September 30, 2025, the company reported a net loss of $81.9 million, or $3.84 per diluted common share, on $65.3 million in total revenue.
- The company ended fiscal 2025 with $188.9 million in cash, cash equivalents, and marketable securities as of September 30, 2025, and expects to fund operations into fiscal 2029.
- Enanta announced EPS-3903 as a lead development candidate for type 2 immune-driven diseases, targeting an IND filing in the second half of 2026, and EDP-978 as a clinical candidate for mast-cell driven diseases, with an IND filing planned for Q1 2026.
- The company also reported positive topline data for its RSVHR study of zelicapavir and successfully closed an upsized public offering in October 2025, raising $74.8 million in gross proceeds.
Nov 17, 2025, 9:15 PM
Quarterly earnings call transcripts for ENANTA PHARMACEUTICALS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more